American Association for Cancer Research
Browse
crc-22-0259-s04.pdf (26.04 kB)

Figure S4 from Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia

Download (26.04 kB)
journal contribution
posted on 2023-04-04, 02:05 authored by Kazuharu Kamachi, Hiroshi Ureshino, Tatsuro Watanabe, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Kazunori Kawasoe, Toshimi Hoshiko, Yuta Yamamoto, Yuki Kurahashi, Shinya Kimura

Figure S4. HL and KG1a cells were exposed to vehicle (Cont), 1.0 mM of OR21 (OR 1), 0.1 μM (HL60) or 0.5 μM (KG1a) of venetoclax (Ven) and OR21 plus venetoclax (OR+Ven). Then mitochondrial membrane potential (MMP) was measured by flow cytometry. Venetoclax decreased MMP levels in HL60 and KG1a, while OR21 did not affect MMP levels in both monotherapy and combination. *p<0.05. n.s. indicated not significant.

Funding

Shinnihon Foundation of Advanced Medical Treatment Research (公益財団法人 新日本先進医療研究財団)

Takeda Science Foundation (TSF)

Japan Medical Association (JMA)

MEXT | Japan Society for the Promotion of Science (JSPS)

Ohara Pharmaceuticals (Ohara)

History

ARTICLE ABSTRACT

The standard treatment for elderly patients with AML is Ven combined with HMAs. OR21, a new oral HMA plus Ven showed synergistic antileukemia effects in vitro and vivo, suggesting that the combination of OR2100 plus Ven is a promising candidate oral therapy for AML.

Usage metrics

    Cancer Research Communications

    Categories

    Keywords

    Hematological CancersLeukemiasDrug TargetsCell SignalingCell Death And Senescencebcl-2 pathways

    Licence

    CC BY

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC